Clinical Trial Update: Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy [Phase 2]

View source ↗

Summary

A Phase 2 trial of combining lapatinib with Caelyx in patients with advanced metastatic breast cancer after trastuzumab failure was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Caelyx (liposomal doxorubicin)
• Lapatinib (Tykerb) (lapatinib)

Snippet

Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED